HC Wainwright & Co. Downgrades SpringWorks Therapeutics to Neutral, Lowers Price Target to $47
Author: Benzinga Newsdesk | April 30, 2025 07:41am
HC Wainwright & Co. analyst Robert Burns downgrades SpringWorks Therapeutics (NASDAQ:SWTX) from Buy to Neutral and lowers the price target from $74 to $47.